DermYoung and Eden MedSpa announce the launch of their “Together We Are Love, Together We Will Heal,” campaign which aims to provide NYC first responders with facials and take-home skincare kits for those experiencing skin damage and irritation due to PPE usage.
Bluestone Sunshields is helping fill the gaps of PPE available to those working on the frontlines of the COVID-19 pandemic by converting their UV ray-blocking visors into clear face shields.
In this week's edition we take a look at the world of injectables, the effects diabetes can have on the skin and how to correctly administer an at-home chemical peel.
In part two of our interview with Amy Paller, M.D., she describes how she is staying informed about the latest COVID-19 research as it relates to the field, and shares some resources other dermatologists may find helpful during this crisis.
DMK Skin Care announces the donation of their new sanitizer spray for all licensed clinics. The product is optimized to sanitize clothing, surfaces and skin.
Amy Paller, M.D., discusses the pernio-like lesions associated with possible COVID-19 infection in younger individuals.
The U.S. FDA has granted an emergency use authorization to Everlywell Inc., to conduct and collect at-home testing for COVID-19.
The American Academy of Dermatology (AAD) announces the debut of their AAD VMX 2020, a virtual meeting being held June 12-14 in lieu of the annual AAD conference that was set to take place in March in Denver but cancelled due to COVID-19 concerns.
A new way to avoid contact with contaminated surfaces is now available through 5th Axis, a San Diego, Calif.-based machinery manufacturer. The company has created the StepHandle, a door handle that can be operated with a foot.
Ortho Dermatologics announces the U.S. FDA supplemental New Drug Application approval for efinaconazole 10% (JUBLIA) for the treatment of onychomycosis, a fungal toenail infection, in patients 6 years and older.
Gilead announces results from their phase 3 trial investigating different dosing durations for the investigational antiviral drug remdesivir.
A new symptom is popping up in COVID-19 patients. The virus can reportedly affect not only the lungs, but other internal organs as well as the senses – and now dermatologists are observing skin reactions in patients with the disease.
George Martin, M.D., dermatologist and program director for the Maui Derm meetings, has been working with the Maui Derm faculty, immunologists and members of industry to share emerging data regarding the novel coronavirus with the dermatology community. Listen to his insights in this video.
In combatting the pandemic, dermatologists must take critical steps to adapt operations while still providing essential patient care and preventing exposure in o ffice settings, experts say.
Jules Lipoff, M.D., dermatologist and assistant professor of clinical dermatology, Penn Medicine, discusses telemedicine in the era of COVID-19.
Governments and the scienti fic community are racing to identify new and existing drugs that might help flatten the curve and save lives. Read from experts as they discuss the latest news and research surrounding possible treatments for COVID-19.
The American Medical Association announces new resources for private practice physicians during the COVID-19 pandemic.
Experts sent a letter to the White House Coronavirus Task Force March 24, outlining concerns about a growing shortage of medications required for managing patients with lupus and rheumatoid arthritis after President Donald Trump said in a March 19 press conference that the anti-malaria drug hydroxychloroquine could treat COVID-19.
As the number of patients infected with COVID-19 continues to rise, several experts are relaying data they say may save lives and change the course of this pandemic. According to Drs. George Martin, Ted Rosen, Sheila Fallon-Friedlander, Albert Yan, and James Treat, recent data provides evidence of the use of HCQ, its dosing, as well as epidemiology insights that will serve all healthcare practitioners in the fight against the novel coronavirus, COVID-19.
The Journal of Drugs in Dermatology is making additional resources available to medical professionals who wish to continue their education in light of medical conference cancelations due to COVID-19.
As the national pandemic continues to escalate, the American Academy of Dermatology is actively compiling resources related to the novel coronavirus to support its members and their practices.
The American Academy of Dermatology (AAD) has issued interim recommendations for practitioners to balance the risk of immunosuppression with the risk of disease flare amid COVID-19 pandemic.
The Dermatology Innovation Forum has announced its cancellation amid global spread of the coronavirus.
The American Academy of Dermatology Board of Directors has decided to cancel the 2020 Annual Meeting in Denver due to coronavirus concerns.
It’s known that combination therapies can be used to create ideal treatment outcomes, but according to Dr. Suneel Chilukuri, results may also last longer than originally thought.
Millennials think of aesthetic treatments no differently than other beauty appointments, according to Dr. Ava Shamban. These are their top facial concerns.
The FDA announced it has accepted a priority review of dupilumab for the treatment of moderate-to-severe AD in pediatric patients 6 to 11 years of age. The drug is already approved for treatment of AD in adolescents and adults.
In a skit depicting Carnac the Magnificent, Drs. Rosen and Bhatia presented on 2020's new drugs and technologies at the current Maui Derm for Dermatologists, all with a magical twist.